Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 5/20 | 0.70 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.54 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL81404 | 1.00 | TRPA1 (0.70) | TRPA1RIPK1TAAR1AOC3KDM4E | |
| SCHEMBL8235394 | 1.00 | TRPA1 (0.70) | TRPA1RIPK1TAAR1AOC3KDM4E | |
| SCHEMBL8155333 | 0.87 | TRPA1 (0.56) | TRPA1RIPK1 | |
| SCHEMBL624310 | 0.86 | TRPA1 (0.60) | TRPA1RIPK1TAAR1AOC3KDM4E | |
| SCHEMBL30148108 | 0.86 | TRPA1 (0.60) | TRPA1RIPK1TAAR1AOC3KDM4E | |
| SCHEMBL6280516 | 0.85 | RIPK1 (0.67) | TRPA1RIPK1TAAR1AOC3 | |
| SCHEMBL1144321 | 0.85 | TRPA1 (0.58) | TRPA1RIPK1TAAR1AOC3ALDH1A1 | |
| SCHEMBL21778163 | 0.84 | TRPA1 (0.53) | TRPA1RIPK1KDM4ELMNA | |
| SCHEMBL29263718 | 0.83 | TRPA1 (0.56) | TRPA1RIPK1TAAR1AOC3ALDH1A1 | |
| SCHEMBL16702621 | 0.83 | TRPA1 (1.00) | TRPA1RIPK1TAAR1AOC3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421200-B2 | Manganese-catalysed hydrogenation of esters | UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) | 2025-09-23 | — | — | US | disclosed |
| CN-120136669-A | Manganese catalyzed ester hydrogenation | 圣安德鲁斯大学董事会 | 2025-06-13 | — | — | CN | disclosed |
| EP-3737663-B1 | MANGANESE-CATALYSED HYDROGENATION OF ESTERS | UNIV COURT UNIV ST ANDREWS (GB) | 2023-02-22 | — | — | EP | disclosed |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-05-11 | — | — | US | disclosed |
| US-20210053932-A1 | MANGANESE-CATALYSED HYDROGENATION OF ESTERS | UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) | 2021-02-25 | — | — | US | disclosed |
| EP-3737663-A1 | MANGANESE-CATALYSED HYDROGENATION OF ESTERS | University Court of The University of St Andrews (GB) | 2020-11-18 | — | — | EP | disclosed |
| CN-111587238-A | Manganese catalyzed ester hydrogenation | 圣安德鲁斯大学董事会 | 2020-08-25 | — | — | CN | disclosed |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-10-29 | — | — | US | disclosed |
| US-10301317-B2 | Inhibitors of ERK and methods of use | KURA ONCOLOGY, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20190047990-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-02-14 | — | — | US | disclosed |
| US-8309545-B2 | Benzofuran potassium channel blockers and uses thereof | BIONOMICS LIMITED (AU) | 2012-11-13 | — | — | US | disclosed |
| US-8217189-B2 | Chromenone potassium channel blockers and uses thereof | BIONOMICS LIMITED (AU) | 2012-07-10 | — | — | US | disclosed |
| US-20100087430-A1 | NOVEL BENZOFURAN POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2010-04-08 | — | — | US | disclosed |
| US-20090298931-A1 | NOVEL CHROMENONE POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2009-12-03 | — | — | US | disclosed |
| WO-2008040058-A1 | NOVEL CHROMENONE POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2008-04-10 | — | — | WO | disclosed |
| EP-1173170-A4 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2002-05-29 | — | — | EP | disclosed |
| EP-1173170-A1 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2002-01-23 | — | — | EP | disclosed |
| US-6265434-B1 | ANTIINFLAMMATORY AGENTS | MERCK & CO., INC. | 2001-07-24 | — | — | US | disclosed |
| WO-2000059503-A1 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | TRPA1 3831/4885RIPK1 1464/4885TAAR1 685/4885 |
| US-10301317-B2 | Inhibitors of ERK and methods of use | MAP3K1, MAP3K2, MAP3K6 | TRPA1 4794/4885RIPK1 689/4885TAAR1 4287/4885 |
| US-20100087430-A1 | NOVEL BENZOFURAN POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | KCNA3, KCNB1, KCNK3 | TRPA1 66/4885RIPK1 1762/4885TAAR1 3460/4885 |
| US-12421200-B2 | Manganese-catalysed hydrogenation of esters | ADH5, HDHD5, ADH1A | TRPA1 4233/4885RIPK1 3876/4885TAAR1 1743/4885 |
| US-20190047990-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | TRPA1 3831/4885RIPK1 1464/4885TAAR1 685/4885 |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | TRPA1 3925/4885RIPK1 1521/4885TAAR1 652/4885 |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | TRPA1 3831/4885RIPK1 1464/4885TAAR1 685/4885 |
| US-20210053932-A1 | MANGANESE-CATALYSED HYDROGENATION OF ESTERS | ADH5, HDHD5, ADH1A | TRPA1 4233/4885RIPK1 3876/4885TAAR1 1743/4885 |
| US-20090298931-A1 | NOVEL CHROMENONE POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | KCNK3, KCNA3, KCND3 | TRPA1 82/4885RIPK1 1391/4885TAAR1 1374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.